5 January 2023
ErVaccine closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023
ErVaccine Technologies, a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, which develops next-generation therapeutic...